Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| ARUP Laboratories, |
RCV001000719 | SCV001157764 | likely pathogenic | Polycystic kidney disease, adult type | 2018-07-23 | criteria provided, single submitter | clinical testing | The PKD1 c.11249G>C; p.Arg3750Pro variant, is reported in the literature in a single individual affected with autosomal dominant polycystic kidney disease (Heyer 2016). This variant is absent from general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. Another variant at this codon (c.11249G>A; p.Arg3750Gln) has been reported in multiple individuals with ADPKD and is considered pathogenic (Audrezet 2012, Bataille 2011, Cornec-Le Gall 2013, Hoefele 2011). The arginine at codon 3750 is moderately conserved and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Based on available information, this variant is considered to be likely pathogenic. References: Audrezet MP et al. Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat. 2012 Aug;33(8):1239-50. Bataille S et al. High Resolution Melt analysis for mutation screening in PKD1 and PKD2. BMC Nephrol. 2011 Oct 18;12:57. Cornec-Le Gall E et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013 May;24(6):1006-13. Heyer CM et al. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 Sep;27(9):2872-84. Hoefele J et al. Novel PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2011 Jul;26(7):2181-8. |